Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Evolus, Inc. Common Stock

EOLS

Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.

Last trade $6.60
Day change -$0.03 (-0.45%)
Day range $6.29 – $6.65
Volume 382,644
Market cap $439M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$438.83M
Price / earnings
—
Price / book
-11.6×
Price / sales
1.35×
EV / sales
1.74×
EV / EBITDA
-112.82×

Profitability

Earnings per share
-$0.47
Return on assets
-10.96%
Return on equity
82.28%
Dividend yield
0%

Liquidity and leverage

Debt / equity
-4.5×
Current ratio
1.42×
Quick ratio
0.84×
Cash ratio
0.29×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$5.6M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for EOLS, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$77.95M$84.08M$73.14M$90.3M$68.97M$69.39M$68.52M$78.95M
Cost of revenue$27.27M$26.9M$24.24M$31.01M$23.13M$24.07M$21.87M$26.31M
Gross profit$50.69M$57.18M$48.9M$59.29M$45.84M$45.32M$46.66M$52.63M
Selling, general and administrative$52.92M$57.05M$51.98M$54.66M$52.82M$56.68M$56.64M$50.24M
Research and development$3.02M$1.89M$2.24M$3.48M$2.05M$1.84M$2.21M$2.43M
Total operating expenses$59.11M$60.47M$55.75M$55.07M$57.34M$59.44M$61.83M$54.95M
Operating income-$8.43M-$3.29M-$6.85M$4.22M-$11.5M-$14.12M-$15.17M-$2.31M
Interest expense-$4.25M-$4.17M-$3.98M-$3.98M-$4.09M-$7.21M-$4.42M-$4.57M
Income before taxes-$12.23M-$8.21M-$10.42M$515K-$15.57M-$17.09M-$18.82M-$6.35M
Income taxes$285K-$154K$256K$385K$167K$53K$72K$440K
Net income-$12.52M-$8.05M-$10.67M$130K-$15.74M-$17.14M-$18.89M-$6.79M
Net income attributable to common shareholders-$12.52M-$8.05M-$10.67M$130K-$15.74M-$17.14M-$18.89M-$6.79M
EBITDA-$6.04M-$957K-$4.5M$6.47M-$8.11M-$12.39M-$13.61M-$940K
Basic earnings per share-$0.19-$0.12-$0.16$0.00-$0.24-$0.27-$0.30-$0.11
Diluted earnings per share-$0.19-$0.12-$0.16$0.00-$0.24-$0.27-$0.30-$0.11

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS

Pomerantz LLP is investigating Evolus, Inc. for potential securities fraud following an FDA warning letter on October 2, 2026, that flagged misleading Instagram promotion of its wrinkle treatment Jeuveau. The FDA objected to false claims about the product's efficacy and safety information minimization. Evolus's stock fell 7.15% to $7.14 per share on the news.

Zacks Investment Research

UTMD Trades at a Premium to the Industry: How to Play the Stock?

Utah Medical Products (UTMD) trades at a premium valuation of 4.05X EV/sales versus industry average of 2.68X. While the company benefits from strong margins (58.2% gross margin), a debt-free balance sheet with $87.5M in cash, and strategic acquisitions, it faces near-term headwinds including 12.3% revenue decline, major customer losses, and projected 10-13% revenue decline for 2026. Long-term investors may hold, but new investors should await a better entry point.

GlobeNewswire Inc.

AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Society

AEON Biopharma announced presentation of analytical and functional data supporting biosimilarity of ABP-450 to BOTOX® at the American Headache Society meeting. The data demonstrates highly similar biological activity through multiple analytical approaches, with LC-MS peptide mapping showing 93%-99% sequence coverage and LD50 potency assay results falling within equivalence criteria established from BOTOX® reference results.

Benzinga

Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing It

Conexeu Sciences Inc. (CNXU) commenced trading on Nasdaq on May 21, 2026, as a regenerative tissue platform company. The company's proprietary CXU™ extracellular matrix platform is designed to scale across multiple markets including wound care, breast reconstruction, and aesthetic medicine without reformulation. The company targets a 510(k) submission in early 2027 and holds issued patents across major markets with no royalty obligations.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.